Northern Exposure PR
We are the leading public relations company serving the life science, pharmaceutical and technology industries.Northern Exposure is the leading public relations company serving the life science, pharmaceutical and technology industries.
Twenty years experience maximising clients’ media exposure and advising on subjects from press handling, marketing strategy and reputation management
Northern Exposure Public Relations is uniquely skilled in assisting clients in all public relations requirements
Meet Our Team
Richard Kerns
Managing Director
Richard has twenty five years’ experience working with life science companies and organisations around the globe, both independently and within larger agencies.
Edward Dutton
Vice President
Ed has over fifteen years experience of working within the pharmaceutical industry, both as a laboratory chemist and in sales and marketing roles within contract research organisations, contract manufacturers and technology based companies.
Sarah Houlton
Technical Consultant in Residence
Sarah has a degree and PhD in chemistry from Imperial College London, and worked as a drug discovery chemist in the pharmaceutical industry. As a science journalist, she has been writing about the pharmaceutical, biotech and chemical industries for more than twenty years.
Our Services
NEPR can assist clients in numerous manners, either on a retained agency basis or through project work around events. Activities include:
Planning & research, web content creation, media relations, technical articles, thought leadership articles, trade show and event management and support, social media, product launches, crisis management & more.
Contact us today to find out how we can assist you
Our Clients
Client News
04/01/2019 Catalent Invests $200 Million to Expand Biologics Capacity and Capabilities
12/02/2019 SGS to Conduct its First Malaria Human Challenge Trial in Belgium
13/02/2019 Catalent Names Alessandro Maselli President and Chief Operating Officer
18/02/2019 Catalent Receives P&G External Business Partner of the Year Award
14/03/2019 Cambrex Completes Expansion and Manufacturing Capability Upgrades in Milan
21/03/2019 Catalent Signs CEO Action for Diversity and Inclusion Pledge
01/04/2019 Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma
10/04/2019 Cambrex Completes Highly Potent API Manufacturing Facility at Charles City, IA
15/04/2019 Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
23/04/2019 Cambrex Completes New Quality Control Laboratory for Generic API Development in Milan
23/04/2019 Catalent Invests $14 Million at its Eberbach, Germany Softgel Facility
30/04/2019 SGS Implements Veeva Vault Clinical Trial Management System Across its Global Network
07/05/2019 Catalent Receives RoSPA Silver Award for its Health and Safety Practices
09/05/2019 Catalent Achieves Global ISO Accreditation
20/05/2019 Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion
19/06/2019 Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy
09/07/2019 Catalent Extends Global Commercial Spray Drying Capabilities in Europe
30/07/2019 Cambrex to Double Size of Edinburgh Solid Form Screening Facility
07/08/2019 Cambrex to be Acquired by the Permira Funds for $60.00 per Share in Cash
23/08/2019 SGS Life Sciences Shortlisted as Finalist in 2019 Clinical Research News European Innovations Awards
05/09/2019 Catalent to Open New Clinical Supply Facility in San Diego
12/09/2019 Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board
17/09/2019 SGS Appoints Steven Thys as Director of Global Clinical Operations
02/10/2019 IDEXX Water Appoints Fisher Scientific channel, part of Thermo Fisher Scientific, as Distributor of Microbiology Testing Products in the EMEA Region for Industrial Markets
04/11/2019 Catalent Biologics Launches GPEx® Boost Cell Line Expression Technology to Improve Titers and Cell-Specific Productivity
14/11/2019 Cambrex Wins Third API Development Award at CPhI Worldwide
19/11/2019 Catalent Appoints Corporate Development and Science Leaders to Drive Growth and Innovation
21/11/2019 Catalent to Supply BeiGene’s BTK Inhibitor BRUKINSA™ (zanubrutinib)
04/12/2019 Cambrex Announces Completion of Acquisition by the Permira Funds
12/12/2019 Catalent Launches New CTSuccess™ Service to Guide Sponsors to Smarter Clinical Trial Supply Planning
Upcoming Events
NEPR will be attending the following events:
CPhI North America
April 30–May 2, 2019
Chicago, IL
Healthcare Estates
October 8 – 9, 2019
Manchester, UK
CPhI Worldwide
November 5 – 7, 2019
Frankfurt, Germany
about 1 year ago | @NrthnExposurePR